Derived Analysis Results

Benefit-sharing from DSI rests on the provider country's national framework. Where it requires bilateral benefit-sharing for DSI, those terms apply. Where it gives effect to the CBD multilateral mechanism, users of its publicly available DSI should share benefits through it: all users non-monetary benefits, as appropriate, and commercial users above set size thresholds also monetary contributions to the Cali Fund. Where it is silent on DSI, the position is not yet settled: check with the country's competent national authority, through the ABS service. Any terms agreed when the genetic resources were accessed still apply. Access and benefit-sharing questions are handled by the ABS service, not by the DataBank. Learn more →

A node's own derived bioinformatics-analysis outputs — e.g. an SSR/microsatellite discovery archive run against an existing genome assembly — pooled from every node that has registered one. Each result is a generic, tool-agnostic entry (the analysis type itself is free text, not a fixed list), linked to the species it was run against and, optionally, the specific genome/transcriptome record it was derived from. Models trained across nodes by federated training appear here too (analysis type federated_training); a model may span several species.

Have data of this kind? How to contribute data →

Showing results for Staphylococcus haemolyticus only.